Author

Wilfried Reichardt

University of FreiburgORCID 0000-0002-8888-399XUnclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:host-pathogen & immune response· 1 Research Focus:metabolism & bioenergetics· 1 Organism:mouse· 1

Frequent Co-Authors

Asma Y. AlrawashdehiD· 2 shared Dietrich Alexander RuessiD· 2 shared Dominik von ElverfeldtiD· 2 shared Geoffroy AndrieuxiD· 2 shared Huda Jumaa· 2 shared Melanie BoerriesiD· 2 shared Philipp HafneriD· 2 shared Solène BessoniD· 2 shared

Activity by Year

2026-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

Asma Y. AlrawashdehORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

ImmunologybioRxivPreprintMay 27, 2026

Immunomodulatory impact of PTPN11/SHP2-based vertical RAS-MAPK pathway inhibition in pancreatic cancer

Asma Y. Alrawashdeh, Xun Chen, Philipp Hafner…·Dietrich Alexander Ruess

This study investigates the immunomodulatory effects of SHP2-based vertical RAS pathway inhibition in pancreatic cancer, revealing both immune-activating and suppressive changes that evolve with treatment.

DOI 10.64898/2026.05.23.727401

humanmouse

𝕏 PostBluesky

Cancer BiologySignal Transduction and Targeted TherapyPeer-reviewedJan 16, 2026

Vertical RAS-pathway inhibition in pancreatic cancer drives therapeutically exploitable mitochondrial alterations

Philipp Hafner, Steffen Johannes Keller, Xun Chen…·Dietrich Alexander Ruess

This study shows that dual SHP2/MEK inhibition in pancreatic cancer causes mitochondrial changes and ROS elevation, leading to a therapy-resistant state that can be targeted with GPX4 inhibition.

9 citationstop 1%

humanbulk RNA-seq

𝕏 PostBluesky